| Journal & Year |
Link |
Authors |
Title |
|
| Journal of Health Insurance, 2024, 1, e1 |
10.34172/jhi.5 |
Darvishi A., Heshmat R. |
Optimizing Health Insurance Capacity for Noncommunicable Diseases in Iran: A Vital Imperative |
1 |
| BMC Public Health, (2024) 24:926 |
https://doi.org/10.1186/s12889-024-18452-7 |
Darvishi A. , Nikkhah A. , Mahmudimanesh M. , Zargar Balajam N. , Shafiee G. and Heshmat R. |
Socioeconomic inequalities in type 2 diabetes mellitus: a study based on a population-based survey in Iran |
2 |
| CURRENT MEDICAL RESEARCH AND OPINION, Revised 29 February 2024 Accepted 18 March 2024 |
https://doi.org/10.1080/03007995.2024.2333425 |
Heshmat R., Darvishi A., Abdi Dezfouli R., Nikkhah A., Radmanesh R. & Moslemi E. |
A short-term economic evaluation of early insulin therapy compared to oral anti-diabetic drugs in order to reduce the major adverse events in type 2 diabetes patients in Iran |
3 |
| Health Economics Review (2024) Published online: 09 November 2023 |
https://doi.org/10.1186/s13561-023-00463-6 |
Darvishi A, Daroudi R, Fazaeli AA |
Cost-utility analysis of Palbociclib + letrozole and Ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model |
4 |
| BMC Public Health 23, 819 (2023) |
https://doi.org/10.1186/s12889-023-15693-w |
Darvishi A., Shafiee G., Zargar-Balajam N., Rezaei-Hemami M., Ostovar N., Heshmat R |
Cost-effectiveness analysis of sarcopenia management interventions in Iran |
5 |
| Iran J Public Health. 2023;52(2):407-419 |
https://doi:10.18502/ijph.v52i2.11894 |
Asadollahi M, Darvishi A, Azimi A, Annabi M, Jafariazar Z, Heshmat R |
Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019 |
6 |
| Expert Review of Pharmacoeconomics & Outcomes Research (2023) Published online: 28 Aug 2023 |
https://doi.org/10.1080/14737167.2023.2251689 |
Daroudi R, Mousavi MT, Shirazikhah M, Alizadeh Zarei M, Hendi HR, Joghataei F, Darvishi A |
Cost-utility analysis of multiple sclerosis rehabilitation in Iran |
7 |
| Expert Review of Pharmacoeconomics & Outcomes Research (2023) |
http://dx.doi.org/10.1080/14737167.2023.2263167 |
Darvishi A, AbdiDezfouli R, Fazaeli AA, Daroudi R |
Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran? |
8 |
| BMC Public Health 23, 1393 (2023) |
https://doi.org/10.1186/s12889-023-16244-z |
Jasemi, S.V., Zandieh, Z, Zandieh N, Rezaei Hemami M, Darvishi A, Abdollahi Z, Heshmat R |
Is vitamin D supplementation program in Iranian schools effective in reducing adolescent depressive symptoms? Cost effectiveness study |
9 |
| Expert Review of Pharmacoeconomics & Outcomes Research (2023) 10 Apr 2023 |
https://doi.org/10.1080/14737167.2023.2200938 |
Darvishi A, Mousavi MT, Abdi Dezfouli R, Shirazikhah M, Alizadeh zarei M, Hendi HR, Joghataei F, Daroudi R |
Cost-benefit analysis of stroke rehabilitation in Iran |
10 |
| Expert Review of Pharmacoeconomics & Outcomes Research (2023) |
https://doi.org/10.1080/14737167.2023.2263164 |
Bashari N, Safaei-Lari M, Darvishi A, Daroudi R |
Cost-Utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran |
11 |
| PLoS ONE, 2022; 17(7): e0270642 |
https://doi.org/10.1371/journal.pone.0270642 |
Darvishi A; Sadeighipoor P; Darroudi A; Daroudi R. |
Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation in the Treatment of Paroxysmal Atrial Fibrillation; Case Study: Iran |
12 |
| BMC Complementary Medicine and Therapies 2022, 22(1): 1-9 |
https://doi.org/10.1186/s12906-021-03474-0 |
Zandieh N, Rezaei Hemami M, Darvishi A, Zarei M, Hasheminejad SM, Abdollahi Z, Heshmat R. |
Economic evaluation of a national vitamin D supplementation program among Iranian adolescents for the prevention of adulthood type 2 diabetes mellitus |
13 |
| Expert Review of Pharmacoeconomics & Outcomes Research 2022, 29 Nov 2022. |
https://doi.org/10.1080/14737167.2023.2152008 |
Kosar Hajian, Ramin Abdi Dezfouli, Ali Darvishi, Ramin Radmanesh & Ramin Heshmat |
Tenecteplase in managing acute ischemic stroke: a long-term cost-utility analysis in Iran |
14 |
| jrehab 2022; 23 (3) :412-433 |
http://rehabilitationj.uswr.ac.ir/article-1-2926-en.html |
Mousavi MT; Daroudi R; Shirazikhah M; Alizadeh zarei M; Hendi HR; Joghataei F; Darvishi A |
Economic evaluation of spinal cord injury (SCI) rehabilitation in Iran. Archives of Rehabilitation |
15 |
| BMC Health Services Research. 2022 Feb 2;22(1):137 |
https://doi:10.1186/s12913-022-07551-z |
Mina Asadollahi; Darvishi A; Azimi AR; Annabi M; Jafariazar Z; Heshmat R |
Estimation the Medical Cost of Multiple Sclerosis in Iran; 2019-2020 |
16 |
| Public Health. 2021. Volume 198, September: 340-347. |
/https://www.sciencedirect.com/science/
article/abs/pii/S0033350621002882
|
Zandieh N, Rezaei Hemami M, Darvishi A, Zarei M, Hasheminejad SM, Abdollahi Z, Heshmat R. |
The Cost-Effectiveness Analysis of a Nationwide Vitamin D Supplementation Program Among Iranian Adolescents for the Adulthood Cardiovascular Diseases Prevention |
17 |
| BMC Public Health. 2021. 21:926. |
https://doi.org/10.1186/s12889-021-10511-7 |
Darvishi A; Rezaei Hemami M; Shafiee G*; Daroudi R; Mohseni M; Hosseini Shekarabi F; Heshmat R. |
Sarcopenia Screening Strategies in Older People: A Cost Effectiveness Analysis in Iran |
18 |